Axsome Therapeutics (AXSM) News Today $91.93 -1.76 (-1.88%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Optimistic Buy Rating for Axsome Therapeutics Driven by Auvelity’s Strong Market Performance and PotentialJanuary 20 at 9:38 AM | markets.businessinsider.com3,000 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by Flower City CapitalFlower City Capital acquired a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 3,000 shares of the company's stock, valued at approximately $2January 20 at 7:56 AM | marketbeat.comZacks Research Has Negative Estimate for AXSM Q3 EarningsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Research analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for Axsome Therapeutics in a report released on Thursday, January 16th. Zacks Research analyst R. Department now expects that the company will post earninJanuary 20 at 1:53 AM | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Receives $129.43 Consensus PT from AnalystsJanuary 18 at 2:51 AM | americanbankingnews.comAnalysts Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) PT at $129.43Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) have earned an average rating of "Buy" from the thirteen ratings firms that are covering the firm, Marketbeat reports. Thirteen research analysts have rated the stock with a buy recommendation. The average 12 month target price amJanuary 18 at 2:16 AM | marketbeat.comWilliam Blair Has Optimistic Outlook of AXSM FY2024 EarningsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Research analysts at William Blair raised their FY2024 EPS estimates for Axsome Therapeutics in a report issued on Monday, January 13th. William Blair analyst M. Minter now forecasts that the company will post earnings of ($4.04) per share fJanuary 17 at 1:32 AM | marketbeat.comWhat is William Blair's Estimate for AXSM FY2024 Earnings?Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities research analysts at William Blair lifted their FY2024 earnings per share estimates for shares of Axsome Therapeutics in a research report issued on Monday, January 13th. William Blair analyst M. Minter now anticipates that the compJanuary 16, 2025 | marketbeat.comAxsome Therapeutics: Strong Performance and Promising Pipeline Drive Buy RatingJanuary 15, 2025 | markets.businessinsider.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Rating of "Buy" from AnalystsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) has earned a consensus rating of "Buy" from the fourteen research firms that are covering the company, Marketbeat.com reports. Fourteen investment analysts have rated the stock with a buy recommendation. The average 1-year target price amonJanuary 15, 2025 | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for Axsome Therapeutics (NASDAQ:AXSM)January 15, 2025 | americanbankingnews.comTruist Financial Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $180.00January 15, 2025 | americanbankingnews.comAxsome Therapeutics (AXSM) Gets a Buy from TD CowenJanuary 14, 2025 | markets.businessinsider.comAxsome Therapeutics (NASDAQ:AXSM) Shares Up 5.3% Following Analyst UpgradeJanuary 14, 2025 | americanbankingnews.comPallas Capital Advisors LLC Purchases Shares of 26,435 Axsome Therapeutics, Inc. (NASDAQ:AXSM)Pallas Capital Advisors LLC bought a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 26,435 shares of the company's stock, valued at aJanuary 13, 2025 | marketbeat.comAxsome Therapeutics: Steady Performance and Growth Potential with Key Catalysts on the HorizonJanuary 13, 2025 | markets.businessinsider.comAxsome Therapeutics (NASDAQ:AXSM) Stock Price Up 5.3% on Analyst UpgradeAxsome Therapeutics (NASDAQ:AXSM) Shares Up 5.3% Following Analyst UpgradeJanuary 13, 2025 | marketbeat.comAxsome Therapeutics' (AXSM) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $133.00 target price on shares of Axsome Therapeutics in a report on Monday.January 13, 2025 | marketbeat.comAxsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net RevenueJanuary 13, 2025 | finance.yahoo.comTruist Financial Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) StockTruist Financial boosted their price objective on Axsome Therapeutics from $150.00 to $180.00 and gave the stock a "buy" rating in a research note on Monday.January 13, 2025 | marketbeat.comOptimistic Buy Rating on Axsome Therapeutics Driven by Auvelity’s Strong Market Performance and Growth PotentialJanuary 11, 2025 | markets.businessinsider.comWhat is Zacks Research's Estimate for AXSM FY2024 Earnings?January 11, 2025 | americanbankingnews.comAxsome Therapeutics price target raised to $180 from $150 at TruistJanuary 10, 2025 | markets.businessinsider.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Bought by JPMorgan Chase & Co.JPMorgan Chase & Co. lifted its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 14.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 212,110 shares of the company's stock after buying an addiJanuary 10, 2025 | marketbeat.comWhat is Zacks Research's Forecast for AXSM FY2024 Earnings?Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Analysts at Zacks Research decreased their FY2024 earnings per share estimates for shares of Axsome Therapeutics in a research report issued on Tuesday, January 7th. Zacks Research analyst R. Department now anticipates that the company willJanuary 9, 2025 | marketbeat.comAxsome Therapeutics price target raised to $140 from $138 at RBC CapitalJanuary 7, 2025 | markets.businessinsider.comAxsome Therapeutics: Strong Buy Recommendation Driven by Promising Pipeline and Market ExpansionJanuary 6, 2025 | markets.businessinsider.comAxsome Therapeutics (NASDAQ:AXSM) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $133.00 target price on shares of Axsome Therapeutics in a research report on Monday.January 6, 2025 | marketbeat.comWilliam Blair Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)January 5, 2025 | markets.businessinsider.comAxsome Therapeutics price target lowered to $122 from $124 at MizuhoJanuary 1, 2025 | markets.businessinsider.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Short Interest UpdateAxsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) was the target of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 6,520,000 shares, a decrease of 7.9% from the November 30th total of 7,080,000 shares. Based on an average daily trading volume, of 488,200 shares, the short-interest ratio is currently 13.4 days.December 31, 2024 | marketbeat.comBuy Rating for Axsome Therapeutics: Promising AXS-05 Efficacy in Alzheimer’s AgitationDecember 31, 2024 | markets.businessinsider.comMizuho Issues Pessimistic Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock PriceMizuho cut their price target on shares of Axsome Therapeutics from $124.00 to $122.00 and set an "outperform" rating for the company in a report on Tuesday.December 31, 2024 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Given "Buy" Rating at HC WainwrightHC Wainwright reiterated a "buy" rating on shares of Axsome Therapeutics in a report on Tuesday.December 31, 2024 | marketbeat.comAxsome reports mixed results for Alzheimer's agitation drugDecember 31, 2024 | seekingalpha.comPositive Outlook for Axsome Therapeutics: AXS-05 Advances Despite SetbacksDecember 31, 2024 | markets.businessinsider.comExpert Outlook: Axsome Therapeutics Through The Eyes Of 8 AnalystsDecember 31, 2024 | benzinga.comSmart Money Is Betting Big In AXSM OptionsDecember 31, 2024 | benzinga.comAxsome Therapeutics: Buy Rating Affirmed Amid Promising Trial Outcomes and Path Forward for AXS-05December 31, 2024 | markets.businessinsider.comAxsome Therapeutics Stock Tumbles As Alzheimer's Studies Reveal Mixed Results: Retail Sentiment Remains BullishDecember 31, 2024 | msn.comAxsome Therapeutics (NASDAQ:AXSM) Shares Gap Down - Here's WhyAxsome Therapeutics (NASDAQ:AXSM) Shares Gap Down - Should You Sell?December 30, 2024 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Receives "Buy" Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $130.00 target price on shares of Axsome Therapeutics in a research report on Monday.December 30, 2024 | marketbeat.comAxsome's drug for Alzheimer's disease agitation meets main goal in late-stage studyDecember 30, 2024 | reuters.comAxsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer's Disease AgitationDecember 30, 2024 | globenewswire.comAxsome Therapeutics (NASDAQ:AXSM) Shares Down 4.8% - Time to Sell?Axsome Therapeutics (NASDAQ:AXSM) Shares Down 4.8% - Time to Sell?December 23, 2024 | marketbeat.comFranklin Resources Inc. Raises Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Franklin Resources Inc. increased its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 47.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 160,534 shares of the company's stock after purchasing an additionaDecember 21, 2024 | marketbeat.comGeode Capital Management LLC Grows Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Geode Capital Management LLC lifted its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 2.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 908,459 shares of the company's stock after purDecember 21, 2024 | marketbeat.comBarclays PLC Buys 45,509 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)Barclays PLC grew its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 279.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 61,785 shares of the company's stock after buying an additionDecember 21, 2024 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Recommendation of "Buy" from BrokeragesShares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) have earned a consensus rating of "Buy" from the fourteen analysts that are covering the company, Marketbeat.com reports. Fourteen research analysts have rated the stock with a buy recommendation. The average 12-month price objectDecember 21, 2024 | marketbeat.comAxsome Therapeutics (AXSM) Gets a Buy from Mizuho SecuritiesDecember 20, 2024 | markets.businessinsider.comAxsome Therapeutics (NASDAQ:AXSM) Trading 4% Higher - Time to Buy?Axsome Therapeutics (NASDAQ:AXSM) Shares Up 4% - Here's What HappenedDecember 17, 2024 | marketbeat.com Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address AXSM Media Mentions By Week AXSM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AXSM News Sentiment▼0.760.44▲Average Medical News Sentiment AXSM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AXSM Articles This Week▼178▲AXSM Articles Average Week Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SMMT News GMAB News VTRS News ITCI News MRNA News RDY News CTLT News SRPT News PCVX News QGEN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AXSM) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AXSM Stock Alerts